Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 3:12 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1355

Shown on this page

Current sort

Live official records

Conditions: Myocarditis Acute, Cancer
Interventions: Abatacept plus, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 29
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more

Conditions: Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
Interventions: Colchicine, Dapsone, Azathioprine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 12
States / cities: Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 9 more

Conditions: Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Interventions: Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam, Digoxin, Rosuvastatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 41
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more

Conditions: Chin Regression, Chin Asymmetry, Jawline Contour Deficit
Interventions: HA Filler; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 22 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fibromyalgia
Interventions: Focused Ultrasound; Device
Lead sponsor: SPIRE Therapeutics Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Ann Arbor, Michigan • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: Lung Cancer (Locally Advanced or Metastatic)
Interventions: Pemefolacianine Cohort 1 in Part A, Pemefolacianin Cohort 2 in Part B; Drug
Lead sponsor: Sunil Singhal; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy; Radiation · Drug · Procedure + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 341
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more

Conditions: Breast Cancer, HER2-positive Breast Cancer
Interventions: trastuzumab-emtansine, Trastuzumab SC, Paclitaxel; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 53
States / cities: San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 44 more

Conditions: Breast Cancer
Interventions: Research Blood Collection; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis, Infections
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Denver, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more

Conditions: New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions: Anakinra, Tocilizumab, Standard medical treatment; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 2 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 25
States / cities: Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more

Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions: Tulmimetostat, Enzalutamide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 22
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 15 more

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists: ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Penn Medicine (University of Pennsylvania)

Filter and sort this campus

Live official records

Abatacept in Immune Checkpoint Inhibitor Myocarditis

A Randomized Multicenter Study for Isolated Skin Vasculitis

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Evaluation of Filler Injection for Chin Profile Enhancement

Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia

Pemefolacianine for IMI of Lung Cancer

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

ATEMPT 2.0: Adjuvant T-DM1 vs TH

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

Remote Sputum Collection in Cystic Fibrosis

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

About this Penn Medicine (University of Pennsylvania) institution page